NEW YORK, July 21 /PRNewswire/ -- Ari Kiev, M.D., president of SPRI Clinical Trials, will be a featured speaker at the upcoming conference Wall Street Unplugged: The Trout Group Investor Seminar -- Management's Guide to Wall Street. The conference will be held on Wednesday, July 30, at Midtown Loft & Terrace, 267 Fifth Avenue in New York. The event is targeted to CEOs and CFOs at private and small and mid-cap life science companies to gain better insight into Wall Street and maximize communication with the investment community.
Dr. Kiev, a peak performance strategist and author of six books on trading psychology, will speak on "Risk-Reward and Valuation of Clinical Stage Compounds: Challenge Your Perspective." His presentation will cover investors' perceptions of early stage companies, advising biotech CEOs on the most effective ways to position clinical trial data to help achieve an optimum valuation.
"Biotech CEOs should challenge their perspectives on the industry and try to see valuation from an investor's point of view rather than that of a scientist," Dr. Kiev said. "There tends to be too much emphasis on hyperbole as to the novelty of the mechanism and the size of the market. Focusing too much on why the stock is going up or down can turn off investors who are looking for greater involvement by the company in the path to success in clinical trials."
Dr. Kiev founded SPRI (http://www.spriclinicaltrials.com) in 1970 to provide top rate clinical trial services to the pharmaceutical and biotech industry. With nearly 40 years of experience managing studies in the New York area, SPRI expanded internationally in 2003. Today, the company conducts studies throughout Eastern and Western Europe.
|SOURCE SPRI Clinical Trials|
Copyright©2008 PR Newswire.
All rights reserved